Viewing Study NCT05485961

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:52 AM
Ignite Modification Date: 2026-01-07 @ 6:18 PM
Study NCT ID: NCT05485961
Status: RECRUITING
Last Update Posted: 2025-12-22
First Post: 2022-07-29
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Sponsor: CSL Behring
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Atherosclerotic Cardiovascular Disease View
None End Stage Kidney Disease View
None Atherosclerotic Cardiovascular Disease in Patients With ESKD View
Keywords:

Keywords

Keyword Brief Keyword Text View
None End Stage Kidney Disease (ESKD) View
None Myocardial infarction (MI) View
None Atherosclerotic cardiovascular disease (ASCVD) View
None Coronary artery disease View
None Peripheral artery disease View
None Diabetes View